African Journal of
Biotechnology

  • Abbreviation: Afr. J. Biotechnol.
  • Language: English
  • ISSN: 1684-5315
  • DOI: 10.5897/AJB
  • Start Year: 2002
  • Published Articles: 12420

Full Length Research Paper

Association of serum MMP-9 with recurrence in patients with resectable esophageal squamous cell carcinoma after chemotherapy or concurrent radiotherapy

Xu Heng
  • Xu Heng
  • Jiangsu Province Institute of Materia Medica, Nanjing Tech University, Nanjing, Jiangsu, 210000, P.R. China.
  • Google Scholar
Xu Xuyun
  • Xu Xuyun
  • Nanjing Rontia Clinical Laboratory, Nanjing, Jiangsu, 210000, P.R. China.
  • Google Scholar
Du Mengjie
  • Du Mengjie
  • Nanjing Rontia Clinical Laboratory, Nanjing, Jiangsu, 210000, P.R. China.
  • Google Scholar
Ma Rong
  • Ma Rong
  • Research Center For Clinical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu 210000, P. R. China.
  • Google Scholar
Wang Qiang
  • Wang Qiang
  • Department of Radiation Oncology, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221005, P. R. China.
  • Google Scholar
Du Aonan
  • Du Aonan
  • Department of Radiation Oncology, Xuzhou Cancer Hospital, Xuzhou, Jiangsu 221005, P. R. China.
  • Google Scholar


  •  Received: 03 July 2022
  •  Accepted: 17 August 2022
  •  Published: 31 August 2022

Abstract

Esophagectomy is a common standard treatment of localized disease. However, local recurrence frequently occurs in patients with advanced esophageal squamous cell carcinoma (ESCC) after operation, resulting in the need for using biomarkers to evaluate recurrence in patients with advanced ESCC during postoperative therapies. This study examined serum matrix metalloproteinase-9 (MMP-9) as a prognosis factor in recurrent patients with advanced ESCC after curative esophagectomy followed by chemotherapy or concurrent radiotherapy. During therapies, patients with recurrent tendencies always have low serum MMP-9 levels compared with those before treatment. For recurrent patients, a difference in recurrence-free survival rate is significant between MMP-9 ≥ 635 ng/mL and MMP-9 < 635 ng/mL before treatment (P < 0.05). Although serum MMP-9 is a negative prognostic factor for patients with recurrence tendency and cannot directly predict recurrence, low serum MMP-9 levels before treatment and after therapies still indicate high recurrence-free survival rate in patients with locally advanced resectable ESCC after chemotherapy or concurrent radiotherapy.

 

Key words: Matrix metalloproteinase-9, esophageal squamous cell carcinoma, recurrence, chemotherapy, survival.